Alzheimer’s Disease/Dementia News

Most self-harm diagnoses occurred within 24 months of a dementia diagnosis, and vice versa, with a greater risk for self-harm within 6 to 12 months after dementia diagnosis, according to findings published in Alzheimer’s & Dementia.

The FDA has approved a supplemental new drug application for Rexulti for the treatment of agitation associated with dementia due to Alzheimer’s disease.

Non-drug interventions for people with Alzheimer’s disease and related dementias effectively lowered the risk for nursing home admission while being cost-effective, according to findings published in Alzheimer’s & Dementia.

Donanemab slowed cognitive and functional decline in early Alzheimer’s disease, according to the results of a phase 3 study.

Choline alfoscerate may improve cognitive function among frail patients with hypertension and attenuate angiotensin II-induced endothelial dysfunction, according to a small study published in the European Journal of Preventive Cardiology.

A biotech company has started the first clinical trial of a sublingual formulation targeting anxiety and depression in people with Alzheimer’s disease, according to a press release.

An online prediction tool may help identify users’ risks for dementia and Alzheimer’s disease based on individual factors, according to a study published in The Journal of Prevention of Alzheimer’s Disease.

ICU COVID-19 survivors showed improvement in disability, frailty and cognitive impairment 1 year after discharge, according to study results published in Annals of the American Thoracic Society.

BOSTON — Now that there are disease-modifying treatments for Alzheimer’s disease, the necessity of identifying “contemporary population-level diagnosis rates of mild cognitive impairment and dementia” is crucial, according to a presenter.

Two FDA advisory committees voted in favor of a supplemental new drug application for Rexulti, ruling there was sufficient data to show treatment for agitation associated with Alzheimer’s dementia outweighed the risks.